Q4 2025 Geron Corp Earnings Call Transcript
Key Points
- RYTELO's fourth quarter net revenue was $48 million, aligning with expectations and contributing to a full-year revenue of $184 million, marking a successful first full commercial year.
- Geron Corp (GERN) projects RYTELO net revenue for 2026 to be between $220 million and $240 million, indicating anticipated growth.
- The company has streamlined operations, reducing projected 2026 operating expenses by approximately $20 million compared to 2025.
- Geron Corp (GERN) has a strong balance sheet with approximately $400 million in cash and marketable securities, providing financial flexibility.
- The strategic restructuring and commercial strategy are designed to enhance RYTELO's market presence, particularly in the second-line lower-risk MDS segment.
- Total operating expenses for 2025 were $255 million, which is high relative to the revenue generated.
- Despite revenue growth, the company is not focused on achieving profitability in 2026, prioritizing investment in commercial strategies instead.
- There is uncertainty regarding the European market strategy due to complexities in HTA processes and MFN pricing impacts.
- The company faces challenges in expanding its market presence, needing to increase both the number of prescribing accounts and repeat prescriptions.
- Geron Corp (GERN) must navigate competitive pressures in the second-line treatment space, particularly with the shift of luspatercept to the first-line setting.
Hello and welcome to the Geron Corporation fourth quarter 2025 earnings call.
(Operator Instructions)
Please be advised that today's conference is being recorded.
I would now like to turn the call over to Dawn Schottlandt, Senior Vice President, Investor Relations and Corporate Affairs. You may begin.
Good morning, everyone. Welcome to the Geron Corporation fourth quarter 2025 earnings conference call.
Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to our 2026 financial guidance, the expected benefits, and other impacts of our strategic restructuring plan, our current RYTELO commercialization strategy, and related opportunities, the therapeutic potential of RYTELO, other anticipated clinical and commercial events and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
